Charles River Laboratories International, Inc. CRL
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Charles River Laboratories International, Inc. (CRL) Revenue growth
Charles River Laboratories International, Inc.'s revenue growth over the twelve months to 30 June 2026 was −0.74%, up 0.1 percentage points from fiscal 2025 (−0.85%). Over the past ten years it has ranged from −1.92% (fiscal 2024) to 23.3% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 7.69% and below the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −0.85% | 1.07 |
| FY2024 | −1.92% | (5.78) |
| FY2023 | 3.86% | (8.45) |
| FY2022 | 12.3% | (8.77) |
| FY2021 | 21.1% | 9.53 |
| FY2020 | 11.6% | (4.12) |
| FY2019 | 15.7% | (6.32) |
| FY2018 | 22.0% | 11.51 |
| FY2017 | 10.5% | (12.86) |
| FY2016 | 23.3% | 18.28 |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −2.72% | (3.90) |
| Mar 2026 | 1.18% | 2.01 |
| Dec 2025 | −0.83% | (0.34) |
| Sep 2025 | −0.49% | (1.08) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GH Guardant Health, Inc. compare | 42.7% |
| MEDP Medpace Holdings, Inc. compare | 24.7% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| DGX Quest Diagnostics Incorporated compare | 9.87% |
| LH Labcorp Holdings Inc. compare | 6.41% |
| RVTY Revvity Inc. compare | 4.05% |
| ICLR ICON PLC compare | 3.26% |
| QGEN QIAGEN N.V. compare | 2.96% |
| CRL Charles River Laboratories International, Inc. | −0.74% |
| Diagnostics & Research industry median | 7.69% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement